Site handover to boost contract production
Print Edition
SHANGHAI Zhangjiang Biotech and Pharmaceutical Base Development Co yesterday officially handed over the biopharmaceutical manufacturing base to Boehringer Ingelheim, which is expected to serve as a contract production site for the German drug company.
The 500 million-yuan (US$78 million) facility in Shanghai’s Zhangjiang High-tech Park is expected to officially start operation in 2017 to conduct clinical trials and produce drugs.
General Manager Wang Lanzhong of the Shanghai company said the facility will serve as a benchmark for biopharmaceutical manufacturing and create a conducive environment for start-up drug research and development companies in the region.
The site will provide contract manufacturing services for local companies which don’t have enough capital to build their own production facility.
Contract manufacturing of biopharmaceutical medicines is part of Shanghai’s initiatives to build the city into an innovative center.
In June, BI signed a memorandum of understanding with the Pudong New Area government to invest 100 million euros (US$124 million) in the next five years to fund the construction and operation of the biotech and pharmaceutical site.
The facility will also be the fourth biopharmaceutical manufacturing site for BI outside the European Union and the United States.
BI said it is confident of securing administrative approval for the contract manufacturing organization license in the near future, but the firm didn’t give a specific timetable.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
